 
                                Jeff F. Lin
@jefflinmd
Gynecologic oncologist at Weill Cornell Medicine in NYC. Husband, human to 2 dog-ters, photography enthusiast, tinkerer. Tweets/opinions are my own
ID: 179373320
https://www.cityofhope.org/jeff-lin 17-08-2010 03:44:55
525 Tweet
744 Followers
357 Following
 
        🚨Another practice-changing study at #ASCO23 🌟DUO-O/The GOG Foundation Inc. 3025 demonstrates improved progression free survival in pts w/ HR deficient AND proficient advanced stage #OvarianCancer treated with durvalumab + olaparib + bevacizumab #gyncsm #ImmunoOnc
 
                        
                    
                    
                    
                 
         
        Congratulations to our very own Thanh Dellinger - leading the vanguard in the treatment of ovarian cancer and other peritoneal surface malignancies!!
 
         
         
         
         
         
        A cost-effective surgery that increase ovarian cancer patient survival by approx. 1 year should be implemented. After a great team effort, I am delighted to say that our article is publish. Thanks to everyone Elizabeth Tremblay IJGC OvarianCancerCanada ijgc.bmj.com/content/33/12/…
 
         
        LIVE #FREE SGO @GynOncJnls webinar Tuesday 2/6 @ 6pm CST. Learn from #SocialMedia experts Gregg Nelson Eleonora Teplinsky, MD Shannon Westin, MD, MPH, FASCO to advance your academic career 🧑🔬🧑💻🤓🧑⚕️ Moderators: me & Eric Rios-Doria, MD Register: connected.sgo.org/content/hashta… #medtwitter #GynCSM #GynOnc
 
                        
                    
                    
                    
                 
         
         
         
         
         
        The SGO Annual Meeting is one month away! ⏳ Can’t wait for the leaders in #GynOncology to discover, unite, empower, & impact here in 📍Seattle! Amanda Nickles Fader, MD Joshua Garrett Cohen Mario M. Leitao, Jr Pedro T Ramirez @GynOncJnls Karen Lu Kenneth H Kim Jeff F. Lin GYN Cancer | #GYNCSM Vaidehi Mujumdar, MD #gyncancer
 
                        
                    
                    
                    
                 
        ![The Lancet Oncology (@thelancetoncol) on Twitter photo NOW OF: In the final 10-yr survival analysis of the OVHIPEC-1 ph 3 RCT of cytoreductive surgery w/o vs w/ HIPEC in pts with adv ovarian cancer, median PFS was 10·7 months (95% CI 9·6–12·0) vs 14·3 months (12·0–18·5); HR 0·63 [95% CI 0·48–0·83], p=0·0008).
thelancet.com/journals/lanon… NOW OF: In the final 10-yr survival analysis of the OVHIPEC-1 ph 3 RCT of cytoreductive surgery w/o vs w/ HIPEC in pts with adv ovarian cancer, median PFS was 10·7 months (95% CI 9·6–12·0) vs 14·3 months (12·0–18·5); HR 0·63 [95% CI 0·48–0·83], p=0·0008).
thelancet.com/journals/lanon…](https://pbs.twimg.com/media/F50GgmXW4AAsADQ.jpg) 
                         
                         
                         
                         
        